The Food and Drug Administration (FDA) recently granted approval for oral Wegovy tablets, expanding treatment options for weight management. In alignment with this approval, Blue Cross Blue Shield of North Dakota (BCBSND) will add Wegovy tablets to its formularies effective Feb. 1, 2026. Coverage is subject to a member’s specific benefit coverage and will not be available prior to Feb. 1, 2026.
Wegovy tablets will be added to the Commercial Formulary and will be placed in a preferred brand tier for the Health Insurance Marketplace and NetResults formularies. Wegovy tablets will require prior authorization (PA). In addition, members transitioning from Wegovy injectable to Wegovy tablets must obtain a new PA for the Wegovy tablets on or after Feb. 1, 2026, even if they have an existing approval for Wegovy injectable.
Questions?
Please review the previously published 2026 Weight Loss Medication Coverage.
